Program
CD19 t-haNK
Its studies are mostly in Leukemia · Lymphoma, Large B-Cell, Diffuse, led by ImmunityBio.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| ImmunityBio | 20 open or running | phase 1since Aug 7, 2019 | Aug 7, 2019 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 7, 2019First study: phase 1 study in Lymphoma, Large B-Cell, DiffuseFirst studyNCT04052061 · United States
- Jul 28, 2025Phase 1 study in LeukemiaNCT07556757 · 4 enrolled · South Africa
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07556757Leukemia · South Africa | 1 | Terminated | Jul 1, 2026 | 4 |
| NCT04052061Lymphoma, Large B-Cell, Diffuse · United States | 1 | Withdrawn | Sep 18, 2021 | 0 |
How it is read
Names in the registry
- “CD19 t-haNK”, 2 entries
Conditions, from the studies’ own filings
- Leukemia, 1 study
- Lymphoma, Large B-Cell, Diffuse, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.